• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Alimera Sciences Inc.

    8/6/24 4:49:51 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALIM alert in real time by email
    425 1 alim20240806_425.htm FORM 425 alim20240806_425.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(D) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): August 6, 2024

    ALIMERA SCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    001-34703

     

    20-0028718

    (State or other Jurisdiction of Incorporation)

     

    (Commission File Number)

     

    (IRS Employer Identification No.)

     

    6310 Town Square, Suite 400

    Alpharetta, Georgia

     

    30005

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    (678) 990-5740

     

    Not Applicable


    (Former name or former address if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, $0.01 par value per share

    ALIM

    The Nasdaq Stock Market LLC

    (Nasdaq Global Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

     

     

     

     

    Item 2.02. Results of Operations and Financial Condition.

     

    On August 6, 2024, Alimera issued a press release regarding its results of operations and financial condition for the three and six months ended June 30, 2024 as well as recent corporate highlights. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

     

    The information in Item 2.02 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

    ‎

     

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)    Exhibits

     

    The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:

     

    Exhibit No.

     

    Description

    99.1

     

    Press Release of Alimera Sciences, Inc. dated August 6, 2024

    104

     

    Cover Page Interactive Data File (embedded within the inline XBRL document)

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    ALIMERA SCIENCES, INC.

       

    Dated: August 6, 2024

    By:

    /s/ Elliot Maltz

     

    Name:

    Elliot Maltz

     

    Title:

    Chief Financial Officer

     

     

     

     
    Get the next $ALIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALIM

    DatePrice TargetRatingAnalyst
    6/25/2024Buy → Neutral
    H.C. Wainwright
    3/25/2024$10.00Buy
    Maxim Group
    10/30/2023$8.00Neutral → Buy
    Alliance Global Partners
    2/25/2022$12.00 → $10.00Buy
    HC Wainwright & Co.
    8/16/2021$16.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ALIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Maltz Elliot

    4 - ALIMERA SCIENCES INC (0001267602) (Issuer)

    9/18/24 9:54:11 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kaseta Michael

    4 - ALIMERA SCIENCES INC (0001267602) (Issuer)

    9/18/24 9:53:50 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Marketing Officer & SVP Holland David returned 187,756 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ALIMERA SCIENCES INC (0001267602) (Issuer)

    9/18/24 9:53:32 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ALIM
    SEC Filings

    View All

    Alimera Sciences downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Alimera Sciences from Buy to Neutral

    6/25/24 7:18:10 AM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Alimera Sciences with a new price target

    Maxim Group initiated coverage of Alimera Sciences with a rating of Buy and set a new price target of $10.00

    3/25/24 7:50:48 AM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alimera Sciences upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded Alimera Sciences from Neutral to Buy and set a new price target of $8.00

    10/30/23 11:06:19 AM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Alimera Sciences Inc.

    15-12G - ALIMERA SCIENCES INC (0001267602) (Filer)

    9/26/24 4:55:34 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Alimera Sciences Inc.

    EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)

    9/23/24 12:15:05 AM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Alimera Sciences Inc.

    EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)

    9/23/24 12:15:02 AM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

    Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in strategic therapeutic area of ophthalmologyAnticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterNew capital structure in place, reducing interest expense by approximately $39 million on an annualized basis (1)ANI maintains its 2024 financial guidance for the standalone Company based on continued momentum across Purified Cortrophin® Gel (Cortrophin

    9/16/24 8:53:27 AM ET
    $ALIM
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

    PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (NASDAQ:ALIM). The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical pr

    9/16/24 6:50:00 AM ET
    $ALIM
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

    PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company") today jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medic

    9/11/24 6:50:00 AM ET
    $ALIM
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    Leadership Updates

    Live Leadership Updates

    View All

    Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.  "As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory," said Rick Eiswirth, Alimera's President and CEO. "Todd brings strong commercial leadership across sales, marketing and market access from b

    12/12/23 7:30:00 AM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alimera Appoints Maggie A. Pax to Its Board of Directors

    ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. "Maggie's experience within growing companies, leading product development, business strategy, supply chain, and commercial teams, along with leading the development of business partnerships, will bring additional operational experience to our board," said Rick Eiswirth, Alimera's Pr

    11/8/23 4:30:00 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alimera Sciences Appoints Jason Werner as Chief Operating Officer

    ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer ("COO"), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations. "Jason has been a strong voice and insightful influence on our board since joining earlier this year, and we

    10/3/23 8:00:00 AM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    Financials

    Live finance-specific insights

    View All

    Alimera Sciences Reports Second Quarter 2024 Results

    Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. ("ANI"). "We are plea

    8/6/24 7:30:00 AM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

    Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from a

    6/24/24 6:50:44 AM ET
    $ALIM
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alimera Sciences Reports First Quarter 2024 Results

    Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our results in this quarter were consistent with our expectations as we continue to integrate YUTIQ into our U.S. business and sup

    5/14/24 7:30:00 AM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

    SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

    9/18/24 4:30:11 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

    SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

    9/16/24 5:10:24 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

    SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

    6/24/24 7:30:16 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care